The Danish Competition Authority fines a pharmaceutical company for abuse of dominance by charging unfair prices (CD Pharma)

CD Pharma has abused its dominant position by increasing their price by 2,000 percent* On 31 January 2018, the Danish Competition Council (“DCC”) ruled in a case concerning CD Pharma’s (a pharmaceutical distributor) abuse of dominant position by charging unfair prices for the drug Syntocinon. Syntocinon contains oxytocin, which is an active substance given to pregnant women in connection with childbirth. From 28 April 2014 until 27 October 2014 CD Pharma increased the price on

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Danish Competition Authority, The Danish Competition Authority fines a pharmaceutical company for abuse of dominance by charging unfair prices (CD Pharma), 31 janvier 2018, e-Competitions January 2018, Art. N° 86544

Visites 557

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues